DOCSLIB.ORG

Gene Expression Changes Associated with Progression and Response in Chronic Myeloid Leukemia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gene Expression Changes Associated with Progression and Response in Chronic Myeloid Leukemia Gene expression changes associated with progression and response in chronic myeloid leukemia Jerald P. Radich*†‡, Hongyue Dai§, Mao Mao§, Vivian Oehler*, Jan Schelter§, Brian Druker†¶, Charles Sawyersʈ, Neil Shahʈ, Wendy Stock**, Cheryl L. Willman†,††, Stephen Friend§, and Peter S. Linsley§ *Divisions of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109; §Rosetta Inpharmatics, Seattle, WA 98109; ¶Oregon Health & Science University, University Center, Portland, OR 97239; ʈUniversity of California, Los Angeles, CA 90095; **University of Chicago School of Medicine, Chicago, IL 60637; ††University of New Mexico Cancer Research and Treatment Center, Albuquerque, NM 87131; and †Southwest Oncology Group, Ann Arbor, MI 48106 Communicated by E. Donnall Thomas, Fred Hutchinson Cancer Research Center, Seattle, WA, December 13, 2005 (received for review June 24, 2005) Chronic myeloid leukemia (CML) is a hematopoietic stem cell Imatinib Mesylate, which suppresses the Ph to the point where it is disease with distinct biological and clinical features. The biologic undetectable by cytogenetic evaluation (a complete cytogenetic basis of the stereotypical progression from chronic phase through remission or CCR) in Ͼ70% of newly diagnosed patients with accelerated phase to blast crisis is poorly understood. We used DNA chronic-phase CML disease (4). The long-term durability duration microarrays to compare gene expression in 91 cases of CML in of such responses is unknown, as is potential for cure with imatinib. chronic (42 cases), accelerated (17 cases), and blast phases (32 Complete molecular response, defined by the absence of the cases). Three thousand genes were found to be significantly (P < Bcr-Abl fusion mRNA by RT-PCR, is unusual in patients with CCR 10؊10) associated with phase of disease. A comparison of the gene (5), and patients who achieve a molecular response, but have signatures of chronic, accelerated, and blast phases suggest that imatinib discontinued, show a relatively rapid reemergence of the progression of chronic phase CML to advanced phase (accel- disease (6). Resistance to imatinib occurs (especially in advanced erated and blast crisis) CML is a two-step rather than a three-step phase disease) often accompanied by point mutations in the process, with new gene expression changes occurring early in tyrosine kinase domain of the abl gene (7). The natural history of accelerated phase before the accumulation of increased numbers such relapses is unknown, although some appear to progress rapidly of leukemia blast cells. Especially noteworthy and potentially into advanced stage disease (8). significant in the progression program were the deregulation of The genetic events that cause the progression of chronic phase to the WNT͞␤-catenin pathway, the decreased expression of Jun B blast crisis CML are largely unknown. Numerous genetic abnor- and Fos, alternative kinase deregulation, such as Arg (Abl2), and an malities have been demonstrated, including the acquisition of increased expression of PRAME. Studies of CML patients who additional chromosomal abnormalities including such as a dupli- Ј relapsed after initially successful treatment with imatinib demon- cation of the Ph , isochromosome 17(p) resulting in the disruption ͞ strated a gene expression pattern closely related to advanced of TP53, and less commonly, the deletion of the p15 p16 tumor phase disease. These studies point to specific gene pathways that suppressor genes (especially in lymphoid blast crisis) and the might be exploited for both prognostic indicators as well as new RUNX1-EV11 fusion (9, 10). Genetic instability is apparent, as targets for therapy. evidenced by the in the additional chromosomal changes that occur with progression, but standard assays of instability, such as alter- genetics ͉ blast crisis ͉ PRAME ͉ Wnt ations in minisatellite repeats, are detected infrequently (11, 12). Unfortunately, clinical and molecular tests cannot predict where on the ‘‘clock’’ of disease progression an individual lies at the time hronic myeloid leukemia (CML) is a hematopoietic stem cell of the diagnosis, and this makes it impossible to adapt therapy to the Cdisease with distinct biological and clinical features. CML degree of risk that faces an individual CML patient. We also cannot usually presents in chronic phase, in which the clonal expansion of yet identify the subset of patients who are most likely to benefit from mature myeloid cells leads to an elevated white blood cell count. a specific treatment option. This study is aimed at determining Without curative intervention, chronic-phase CML will invariably changes in gene expression that occur in the evolution of the chronic transform through a phase of ‘‘acceleration,’’ often heralded by the phase to blast crisis, with the hope of identifying genes and pathways appearance of increased immature myeloid cells in the bone that may be useful as prognostic markers or targets for therapeutics. marrow and peripheral blood, as well as new cytogenetic changes in addition to the Philadelphia chromosome (Ph). Progression then Results proceeds to blast crisis, with immature blast cells overwhelming the Phase-Specific Gene Expression in CML. We first examined the genes production of normal hematopoetic elements. Blast crisis is highly associated with the phase of disease. We used as a reference a pool resistant to treatment, with death generally occurring from infec- of 200 chronic phase bone marrows, and studied 91 individual cases tion and bleeding complications secondary to the absence of of CML in chronic phase (n ϭ 42), accelerated phase by blast count normal granulocytes and platelets. The median time from diagnosis criteria (n ϭ 9) or by the occurrence of additional clonal cytogenetic of chronic phase CML to progression to accelerated phase is Ϸ3–4 changes (n ϭ 8), blast crisis (n ϭ 28), and four cases of blast crisis years, but the range of timing is quite broad, encompassing from 0.5 in remission after chemotherapy. An ANOVA analysis revealed to 15 years (1). Ϸ3,500 genes (from a total of Ϸ24,000 genes) differentially ex- There are several treatment options for CML. All treatments are pressed across the different phases of disease by using a minimum more successful when administered during the chronic phase disease than in accelerated or blast phase. The only known curative therapy for CML is stem cell transplantation, a complex and Conflict of interest statement: No conflicts declared. potentially toxic modality that carries a high potential for morbidity Freely available online through the PNAS open access option. and mortality (2). Nontransplant therapy includes IFN-␣, which Abbreviations: CML, chronic myeloid leukemia; CCR, complete cytogenetic remission. produces a major reduction in the proportion of Ph-positive cells Data deposition: The sequence reported in this paper has been deposited in the Gene and extends the natural history of the disease in Ϸ10–20% of Ontology (GO) database (accession no. GSE4170). patients cases, with some alive and in remission for Ͼ10 years (3). ‡To whom correspondence should be addressed. E-mail: [email protected]. IFN-␣ has largely been replaced by the tyrosine kinase inhibitor, © 2006 by The National Academy of Sciences of the USA 2794–2799 ͉ PNAS ͉ February 21, 2006 ͉ vol. 103 ͉ no. 8 www.pnas.org͞cgi͞doi͞10.1073͞pnas.0510423103 Downloaded by guest on September 30, 2021 Fig. 1. Genes associated with CML progression. Sam- ples from patients with of CML cases in chronic phase, accelerated by cytogenetic criteria only, accelerated phase, blast crisis, and blast crisis ‘‘in remission’’ were compared to a pool of chronic phase RNA (See Mate- rials and Methods for details). Approximately 3,500 genes were significantly associated with progressive disease at a significance level of P Ͻ 10Ϫ11. Each row represents one sample, and each column represents one gene. Red color indicates overexpression relative to the control pool, and green color indicates low expression. statistical significance cutoff of P Ͻ 10Ϫ11 (Fig. 1 and Table 4, which drial genes, RNA-binding genes, and protein biosynthesis genes, is published as supporting information on the PNAS web site). This reflecting the increased proliferation and metabolism of progres- set of genes identified in the progression from chronic to blast phase sive disease. Advanced-phase CML, compared to chronic phase, is referred to here as the ‘‘phase reporter’’ gene set. exhibited a decreased expression of genes involved in structural We examined the proposed biologic function of the genes integrity and adhesion, as well as decreases in expression of genes associated with CML phases by applying a biological annotation involved in inflammatory and immune response. In addition, program based on the gene ontology (GO) and KEGG annotations. several protooncogenes and tumor suppressor genes are differen- The major functional groups of genes in the phase reporter gene set tially expressed in advanced phase CML, including N- and H-ras, are shown in Table 5, which is published as supporting information FLT3, yes, AF1q, CBFB, WT1, ORALOV1, Bcl-2, and PTPN11. on the PNAS web site. The functional groups most highly correlated with disease phase (accelerated͞blast phase relative to chronic CML Appears to Be a ‘‘Two-Step’’ Disease. We examined whether the phase) included increased expression of nuclear genes, mitochon- progression of CML best fit a three-step model as often described MEDICAL SCIENCES Fig. 2. Comparison of CML blasts to normal CD34ϩ cells and correction for the pattern of gene expression. (A) Phase genes were corrected for normal CD34ϩ gene expression (ANOVA, P Ͻ 1 ϫ 10Ϫ8). The gene expression of normal CD34ϩ cells was subtracted from each disease sample. The resulting pattern reflects genes associated with progression independent of normal blast biology. (B) Relative gene expression of the ‘‘top ten’’ genes found to be up-regulated in advanced phase disease compared to chronic phase. Radich et al. PNAS ͉ February 21, 2006 ͉ vol. 103 ͉ no. 8 ͉ 2795 Downloaded by guest on September 30, 2021 in the literature (chronic phase 3 accelerated phase 3 blast crisis), Table 1.
Load more

Recommended publications
  • Histone Isoform H2A1H Promotes Attainment of Distinct Physiological
    Bhattacharya et al. Epigenetics & Chromatin (2017) 10:48 DOI 10.1186/s13072-017-0155-z Epigenetics & Chromatin RESEARCH Open Access Histone isoform H2A1H promotes attainment of distinct physiological states by altering chromatin dynamics Saikat Bhattacharya1,4,6, Divya Reddy1,4, Vinod Jani5†, Nikhil Gadewal3†, Sanket Shah1,4, Raja Reddy2,4, Kakoli Bose2,4, Uddhavesh Sonavane5, Rajendra Joshi5 and Sanjay Gupta1,4* Abstract Background: The distinct functional efects of the replication-dependent histone H2A isoforms have been dem- onstrated; however, the mechanistic basis of the non-redundancy remains unclear. Here, we have investigated the specifc functional contribution of the histone H2A isoform H2A1H, which difers from another isoform H2A2A3 in the identity of only three amino acids. Results: H2A1H exhibits varied expression levels in diferent normal tissues and human cancer cell lines (H2A1C in humans). It also promotes cell proliferation in a context-dependent manner when exogenously overexpressed. To uncover the molecular basis of the non-redundancy, equilibrium unfolding of recombinant H2A1H-H2B dimer was performed. We found that the M51L alteration at the H2A–H2B dimer interface decreases the temperature of melting of H2A1H-H2B by ~ 3 °C as compared to the H2A2A3-H2B dimer. This diference in the dimer stability is also refected in the chromatin dynamics as H2A1H-containing nucleosomes are more stable owing to M51L and K99R substitu- tions. Molecular dynamic simulations suggest that these substitutions increase the number of hydrogen bonds and hydrophobic interactions of H2A1H, enabling it to form more stable nucleosomes. Conclusion: We show that the M51L and K99R substitutions, besides altering the stability of histone–histone and histone–DNA complexes, have the most prominent efect on cell proliferation, suggesting that the nucleosome sta- bility is intimately linked with the physiological efects observed.
    [Show full text]
  • Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino-Like Mouse Models: Tracking the Role of the Hairless Gene
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Doctoral Dissertations Graduate School 5-2006 Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino-like Mouse Models: Tracking the Role of the Hairless Gene Yutao Liu University of Tennessee - Knoxville Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss Part of the Life Sciences Commons Recommended Citation Liu, Yutao, "Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino- like Mouse Models: Tracking the Role of the Hairless Gene. " PhD diss., University of Tennessee, 2006. https://trace.tennessee.edu/utk_graddiss/1824 This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. To the Graduate Council: I am submitting herewith a dissertation written by Yutao Liu entitled "Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino-like Mouse Models: Tracking the Role of the Hairless Gene." I have examined the final electronic copy of this dissertation for form and content and recommend that it be accepted in partial fulfillment of the requirements for the degree of Doctor of Philosophy, with a major in Life Sciences. Brynn H. Voy, Major Professor We have read this dissertation and recommend its acceptance: Naima Moustaid-Moussa, Yisong Wang, Rogert Hettich Accepted for the Council: Carolyn R.
    [Show full text]
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • Genome-Wide Approach to Identify Risk Factors for Therapy-Related Myeloid Leukemia
    Leukemia (2006) 20, 239–246 & 2006 Nature Publishing Group All rights reserved 0887-6924/06 $30.00 www.nature.com/leu ORIGINAL ARTICLE Genome-wide approach to identify risk factors for therapy-related myeloid leukemia A Bogni1, C Cheng2, W Liu2, W Yang1, J Pfeffer1, S Mukatira3, D French1, JR Downing4, C-H Pui4,5,6 and MV Relling1,6 1Department of Pharmaceutical Sciences, The University of Tennessee, Memphis, TN, USA; 2Department of Biostatistics, The University of Tennessee, Memphis, TN, USA; 3Hartwell Center, The University of Tennessee, Memphis, TN, USA; 4Department of Pathology, The University of Tennessee, Memphis, TN, USA; 5Department of Hematology/Oncology St Jude Children’s Research Hospital, The University of Tennessee, Memphis, TN, USA; and 6Colleges of Medicine and Pharmacy, The University of Tennessee, Memphis, TN, USA Using a target gene approach, only a few host genetic risk therapy increases, the importance of identifying host factors for factors for treatment-related myeloid leukemia (t-ML) have been secondary neoplasms increases. defined. Gene expression microarrays allow for a more 4 genome-wide approach to assess possible genetic risk factors Because DNA microarrays interrogate multiple ( 10 000) for t-ML. We assessed gene expression profiles (n ¼ 12 625 genes in one experiment, they allow for a ‘genome-wide’ probe sets) in diagnostic acute lymphoblastic leukemic cells assessment of genes that may predispose to leukemogenesis. from 228 children treated on protocols that included leukemo- DNA microarray analysis of gene expression has been used to genic agents such as etoposide, 13 of whom developed t-ML. identify distinct expression profiles that are characteristic of Expression of 68 probes, corresponding to 63 genes, was different leukemia subtypes.13,14 Studies using this method have significantly related to risk of t-ML.
    [Show full text]
  • Differences for Ectopic Versus Eutopic Cells
    556 RBMO VOLUME 39 ISSUE 4 2019 ARTICLE Chemosensitivity and chemoresistance in endometriosis – differences for ectopic versus eutopic cells BIOGRAPHY Andres Salumets is Professor of Reproductive Medicine at the University of Tartu, and Scientific Head at the Competence Centre on Health Technologies, Tartu, Estonia. He has been involved in assisted reproduction for 20 years, first as an embryologist and later as a researcher. His major interests are endometriosis, endometrial biology and implantation. Darja Lavogina1,2,*, Külli Samuel1, Arina Lavrits1,3, Alvin Meltsov1, Deniss Sõritsa1,4,5, Ülle Kadastik6, Maire Peters1,4, Ago Rinken2, Andres Salumets1,4,7, 8 KEY MESSAGE Akt/PKB inhibitor GSK690693, CK2 inhibitor ARC-775, MAPK pathway inhibitor sorafenib, proteasome inhibitor bortezomib, and microtubule-depolymerizing toxin MMAE showed higher cytotoxicity in eutopic cells. In contrast, 10 µmol/l of the anthracycline toxin doxorubicin caused cellular death in ectopic cells more effectively than in eutopic cells, underlining the potential of doxorubicin in endometriosis research. ABSTRACT Research question: Endometriosis is a common gynaecological disease defined by the presence of endometrium-like tissue outside the uterus. This complex disease, often accompanied by severe pain and infertility, causes a significant medical and socioeconomic burden; hence, novel strategies are being sought for the treatment of endometriosis. Here, we set out to explore the cytotoxic effects of a panel of compounds to find toxins with different efficiency in eutopic versus ectopic cells, thus highlighting alterations in the corresponding molecular pathways. Design: The effect on cellular viability of 14 compounds was established in a cohort of paired eutopic and ectopic endometrial stromal cell samples from 11 patients.
    [Show full text]
  • Reconstructing Cell Cycle Pseudo Time-Series Via Single-Cell Transcriptome Data—Supplement
    School of Natural Sciences and Mathematics Reconstructing Cell Cycle Pseudo Time-Series Via Single-Cell Transcriptome Data—Supplement UT Dallas Author(s): Michael Q. Zhang Rights: CC BY 4.0 (Attribution) ©2017 The Authors Citation: Liu, Zehua, Huazhe Lou, Kaikun Xie, Hao Wang, et al. 2017. "Reconstructing cell cycle pseudo time-series via single-cell transcriptome data." Nature Communications 8, doi:10.1038/s41467-017-00039-z This document is being made freely available by the Eugene McDermott Library of the University of Texas at Dallas with permission of the copyright owner. All rights are reserved under United States copyright law unless specified otherwise. File name: Supplementary Information Description: Supplementary figures, supplementary tables, supplementary notes, supplementary methods and supplementary references. CCNE1 CCNE1 CCNE1 CCNE1 36 40 32 34 32 35 30 32 28 30 30 28 28 26 24 25 Normalized Expression Normalized Expression Normalized Expression Normalized Expression 26 G1 S G2/M G1 S G2/M G1 S G2/M G1 S G2/M Cell Cycle Stage Cell Cycle Stage Cell Cycle Stage Cell Cycle Stage CCNE1 CCNE1 CCNE1 CCNE1 40 32 40 40 35 30 38 30 30 28 36 25 26 20 20 34 Normalized Expression Normalized Expression Normalized Expression 24 Normalized Expression G1 S G2/M G1 S G2/M G1 S G2/M G1 S G2/M Cell Cycle Stage Cell Cycle Stage Cell Cycle Stage Cell Cycle Stage Supplementary Figure 1 | High stochasticity of single-cell gene expression means, as demonstrated by relative expression levels of gene Ccne1 using the mESC-SMARTer data. For every panel, 20 sample cells were randomly selected for each of the three stages, followed by plotting the mean expression levels at each stage.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,799,528 B2 Civin Et Al
    US007799528B2 (12) United States Patent (10) Patent No.: US 7,799,528 B2 Civin et al. (45) Date of Patent: Sep. 21, 2010 (54) THERAPEUTIC AND DIAGNOSTIC Al-Hajj et al., “Prospective identification of tumorigenic breast can APPLICATIONS OF GENES cer cells.” Proc. Natl. Acad. Sci. U.S.A., 100(7):3983-3988 (2003). DIFFERENTIALLY EXPRESSED IN Bhatia et al., “A newly discovered class of human hematopoietic cells LYMPHO-HEMATOPOETC STEM CELLS with SCID-repopulating activity.” Nat. Med. 4(9)1038-45 (1998). (75) Inventors: Curt I. Civin, Baltimore, MD (US); Bonnet, D., “Normal and leukemic CD35-negative human Robert W. Georgantas, III, Towson, hematopoletic stem cells.” Rev. Clin. Exp. Hematol. 5:42-61 (2001). Cambot et al., “Human Immune Associated Nucleotide 1: a member MD (US) of a new guanosine triphosphatase family expressed in resting T and (73) Assignee: The Johns Hopkins University, B cells.” Blood, 99(9):3293-3301 (2002). Baltimore, MD (US) Chen et al., “Kruppel-like Factor 4 (Gut-enriched Kruppel-like Fac tor) Inhibits Cell Proliferation by Blocking G1/S Progression of the *) NotOt1Ce: Subjubject to anyy d1Sclaimer,disclai theh term off thisthi Cell Cycle.” J. Biol. Chem., 276(32):30423-30428 (2001). patent is extended or adjusted under 35 Chen et al., “Transcriptional profiling of Kurppel-like factor 4 reveals U.S.C. 154(b) by 168 days. a function in cell cycle regulation and epithelial differentiation.” J. Mol. Biol. 326(3):665-677 (2003). (21) Appl. No.: 11/199.665 Civin et al., “Highly purified CD34-positive cells reconstitute (22) Filed: Aug. 9, 2005 hematopoiesis,” J.
    [Show full text]
  • Pharmacological Unmasking Microarray Approach-Based Discovery of Novel DNA Methylation Markers for Hepatocellular Carcinoma
    ORIGINAL ARTICLE Oncology & Hematology http://dx.doi.org/10.3346/jkms.2012.27.6.594 • J Korean Med Sci 2012; 27: 594-604 Pharmacological Unmasking Microarray Approach-Based Discovery of Novel DNA Methylation Markers for Hepatocellular Carcinoma Namhee Jung1, Jae Kyung Won2, DNA methylation is one of the main epigenetic mechanisms and hypermethylation of CpG Baek-Hui Kim3, Kyung Suk Suh4, islands at tumor suppressor genes switches off these genes. To find novel DNA methylation Ja-June Jang2, and Gyeong Hoon Kang1,2 markers in hepatocellular carcinoma (HCC), we performed pharmacological unmasking (treatment with 5-aza-2´-deoxycytidine or trichostatin A) followed by microarray analysis 1Laboratory of Epigenetics, Cancer Research Institute, 2Departments of Pathology, 3General in HCC cell lines. Of the 239 promoter CpG island loci hypermethylated in HCC cell lines Surgery, Seoul National University College of (as revealed by methylation-specific PCR), 221 loci were found to be hypermethylated in Medicine, Seoul; 4Department of Pathology, Korea HCC or nonneoplastic liver tissues. Thirty-three loci showed a 20% higher methylation University School of Medicine, Seoul, Korea frequency in tumors than in adjacent nonneoplastic tissues. Correlation of individual Received: 21 November 2011 cancer-related methylation markers with clinicopathological features of HCC patients Accepted: 23 February 2012 (n = 95) revealed that the number of hypermethylated genes in HCC tumors was higher in older than in younger patients. Univariate and multivariate survival analysis revealed that Address for Correspondence: the HIST1H2AE methylation status is closely correlated with the patient’s overall survival Gyeong Hoon Kang, MD Department of Pathology, Seoul National University College of (P = 0.022 and P = 0.010, respectively).
    [Show full text]
  • A Yeast Phenomic Model for the Influence of Warburg Metabolism on Genetic Buffering of Doxorubicin Sean M
    Santos and Hartman Cancer & Metabolism (2019) 7:9 https://doi.org/10.1186/s40170-019-0201-3 RESEARCH Open Access A yeast phenomic model for the influence of Warburg metabolism on genetic buffering of doxorubicin Sean M. Santos and John L. Hartman IV* Abstract Background: The influence of the Warburg phenomenon on chemotherapy response is unknown. Saccharomyces cerevisiae mimics the Warburg effect, repressing respiration in the presence of adequate glucose. Yeast phenomic experiments were conducted to assess potential influences of Warburg metabolism on gene-drug interaction underlying the cellular response to doxorubicin. Homologous genes from yeast phenomic and cancer pharmacogenomics data were analyzed to infer evolutionary conservation of gene-drug interaction and predict therapeutic relevance. Methods: Cell proliferation phenotypes (CPPs) of the yeast gene knockout/knockdown library were measured by quantitative high-throughput cell array phenotyping (Q-HTCP), treating with escalating doxorubicin concentrations under conditions of respiratory or glycolytic metabolism. Doxorubicin-gene interaction was quantified by departure of CPPs observed for the doxorubicin-treated mutant strain from that expected based on an interaction model. Recursive expectation-maximization clustering (REMc) and Gene Ontology (GO)-based analyses of interactions identified functional biological modules that differentially buffer or promote doxorubicin cytotoxicity with respect to Warburg metabolism. Yeast phenomic and cancer pharmacogenomics data were integrated to predict differential gene expression causally influencing doxorubicin anti-tumor efficacy. Results: Yeast compromised for genes functioning in chromatin organization, and several other cellular processes are more resistant to doxorubicin under glycolytic conditions. Thus, the Warburg transition appears to alleviate requirements for cellular functions that buffer doxorubicin cytotoxicity in a respiratory context.
    [Show full text]
  • Transcriptional and Post-Transcriptional Regulation of ATP-Binding Cassette Transporter Expression
    Transcriptional and Post-transcriptional Regulation of ATP-binding Cassette Transporter Expression by Aparna Chhibber DISSERTATION Submitted in partial satisfaction of the requirements for the degree of DOCTOR OF PHILOSOPHY in Pharmaceutical Sciences and Pbarmacogenomies in the Copyright 2014 by Aparna Chhibber ii Acknowledgements First and foremost, I would like to thank my advisor, Dr. Deanna Kroetz. More than just a research advisor, Deanna has clearly made it a priority to guide her students to become better scientists, and I am grateful for the countless hours she has spent editing papers, developing presentations, discussing research, and so much more. I would not have made it this far without her support and guidance. My thesis committee has provided valuable advice through the years. Dr. Nadav Ahituv in particular has been a source of support from my first year in the graduate program as my academic advisor, qualifying exam committee chair, and finally thesis committee member. Dr. Kathy Giacomini graciously stepped in as a member of my thesis committee in my 3rd year, and Dr. Steven Brenner provided valuable input as thesis committee member in my 2nd year. My labmates over the past five years have been incredible colleagues and friends. Dr. Svetlana Markova first welcomed me into the lab and taught me numerous laboratory techniques, and has always been willing to act as a sounding board. Michael Martin has been my partner-in-crime in the lab from the beginning, and has made my days in lab fly by. Dr. Yingmei Lui has made the lab run smoothly, and has always been willing to jump in to help me at a moment’s notice.
    [Show full text]
  • Chimeric Proteins Composed of Jun and CREB Define Domains
    JOURNAL OF VIROLOGY, Oct. 1995, p. 6209–6218 Vol. 69, No. 10 0022-538X/95/$04.0010 Copyright q 1995, American Society for Microbiology Chimeric Proteins Composed of Jun and CREB Define Domains Required for Interaction with the Human T-Cell Leukemia Virus Type 1 Tax Protein MIN JEAN YIN, EVYIND PAULSSEN, JACOB SEELER,† AND RICHARD B. GAYNOR* Departments of Internal Medicine and Microbiology, Divisions of Molecular Virology and Hematology-Oncology, University of Texas Southwestern Medical Center, Dallas, Texas 75235-8594 Received 5 April 1995/Accepted 26 June 1995 The regulation of human T-cell leukemia virus type 1 (HTLV-1) long terminal repeat gene expression is dependent on three cis-acting elements known as 21-bp repeats and the transactivator protein Tax. Mutagen- esis has demonstrated that sequences in each of the 21-bp repeats can be divided into three domains designated A, B, and C. Tax stimulates the binding of CREB to the B domain, which is essential for Tax activation of HTLV-1 gene expression. In this study, we demonstrate that Tax will stimulate the binding of CREB to the HTLV-1 21-bp repeats but does not stimulate CREB binding to the consensus cyclic AMP response element (CRE) element found in the somatostatin promoter. However, Tax stimulates CREB binding to a consensus CRE in the context of the 21-bp repeats, indicating the importance of these sequences in stimulating CREB binding. To determine the mechanism by which Tax stimulates CREB binding and determine potential interactions between Tax and CREB, we used the mammalian two-hybrid system in conjunction with in vitro binding and gel retardation assays.
    [Show full text]
  • Rap1-Mediated Chromatin and Gene Expression Changes at Senescence
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2019 Rap1-Mediated Chromatin And Gene Expression Changes At Senescence Shufei Song University of Pennsylvania Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Biochemistry Commons, and the Cell Biology Commons Recommended Citation Song, Shufei, "Rap1-Mediated Chromatin And Gene Expression Changes At Senescence" (2019). Publicly Accessible Penn Dissertations. 3557. https://repository.upenn.edu/edissertations/3557 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/3557 For more information, please contact [email protected]. Rap1-Mediated Chromatin And Gene Expression Changes At Senescence Abstract ABSTRACT RAP1-MEDIATED CHROMATIN AND GENE EXPRESSION CHANGES AT SENESCENCE The telomeric protein Rap1 has been extensively studied for its roles as a transcriptional activator and repressor. Indeed, in both yeast and mammals, Rap1 is known to bind throughout the genome to reorganize chromatin and regulate gene transcription. Previously, our lab published evidence that Rap1 plays important roles in cellular senescence. In telomerase-deficient S. cerevisiae, Rap1 relocalizes from telomeres and subtelomeres to new Rap1 target at senescence (NRTS). This leads to two types of histone loss: Rap1 lowers global histone levels by repressing histone gene transcription and it also results in local nucleosome displacement at the promoters of the activated NRTS. Here, I examine mechanisms of site-specific histone loss by presenting evidence that Rap1 can directly interact with histone tetramers H3/H4, and map this interaction to a three-amino-acid-patch within the DNA binding domain. Functional studies are performed in vivo using a mutant form of Rap1 with weakened histone interactions, and deficient promoter clearance as well as blunted gene activation is observed, indicating that direct Rap1-H3/H4 interactions are involved in nucleosome displacement.
    [Show full text]